المملكة: “Food and Medicine” is looking to invest with 40 representatives of American medical companies

The CEO of the General Food and Drug Authority, Prof. Dr. Hisham bin Saad Al -Jadati, discussed today in Riyadh, with a delegation that includes about 40 representatives of American medical companies, investment opportunities in the health sector in the Kingdom.
He reviewed the most important fields of investment available in the health sector in the Kingdom.

Health investments

He stressed the commitment of the authority to develop the investment environment, and enable specialized companies in the medical field to grow and expand.

He also reviewed the regulations and regulatory legislation in force in the Kingdom, and the mechanisms for supporting investment in the health sector.

The health sector in Saudi Arabia

This meeting comes within the framework of the authority’s efforts to develop international partnerships and enhance investments in the health sector.
This contributes to improving the quality of health services and supporting the health transformation process in the Kingdom.

Hemophilia patients «B) in Saudi Arabia

The Food and Drug General Authority announced the registration of the hemgenix, to be the first approved genetic treatment for medium and very dangerous hemophilia in the Kingdom.
Himophilia B is a life -threatening disease, a rare genetic disorder caused by a gene that is responsible for the production of the ninth “IX”, a protein that plays a fundamental role in the process of blood clotting and stopping bleeding.